These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 22324734)

  • 1. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
    Vallet S; Witzens-Harig M; Jaeger D; Podar K
    Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
    Schafer PH
    Expert Opin Pharmacother; 2012 Jul; 13(10):1541-2. PubMed ID: 22646699
    [No Abstract]   [Full Text] [Related]  

  • 3. IMiDs: a novel class of immunomodulators.
    Knight R
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
    Palumbo A; Freeman J; Weiss L; Fenaux P
    Expert Opin Drug Saf; 2012 Jan; 11(1):107-20. PubMed ID: 22066855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application and biology of immunomodulatory drugs (IMiDs) in cancer.
    Pan B; Lentzsch S
    Pharmacol Ther; 2012 Oct; 136(1):56-68. PubMed ID: 22796518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [IMiDs in hematology].
    Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
    Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F; Baz R
    Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances of IMiDs in cancer therapy.
    Li S; Gill N; Lentzsch S
    Curr Opin Oncol; 2010 Nov; 22(6):579-85. PubMed ID: 20689431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of thalidomide and its analogues: implications for anticancer therapy.
    Teo SK
    AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
    Wiernik PH
    Curr Treat Options Oncol; 2009 Apr; 10(1-2):1-15. PubMed ID: 19016330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
    List AF
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
    Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
    Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes.
    Castelli R; Cassin R; Cannavò A; Cugno M
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):1-7. PubMed ID: 23153925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The thalidomide saga.
    Melchert M; List A
    Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thalidomide: mechanisms of action and new insights in hematology].
    Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
    Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
    Leitch HA; Buckstein R; Shamy A; Storring JM
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.